Mesoblast limited Company Profile (ASX:MSB)

About Mesoblast limited (ASX:MSB)

Mesoblast limited logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: ASX:MSB
  • CUSIP: N/A
  • Web: www.mesoblast.com/
Average Prices:
  • 50 Day Moving Avg: A$2.05
  • 200 Day Moving Avg: A$2.10
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -1,085.90%
  • Return on Equity: -7.47%
  • Return on Assets: -5.86%
 
Frequently Asked Questions for Mesoblast limited (ASX:MSB)

What is Mesoblast limited's stock symbol?

Mesoblast limited trades on the ASX under the ticker symbol "MSB."

Who are some of Mesoblast limited's key competitors?

Who are Mesoblast limited's key executives?

Mesoblast limited's management team includes the folowing people:

  • Silviu Itescu, Chief Executive Officer, Executive Director
  • William A. Burns, Vice Chairman of the Board
  • Paul Hodgkinson, Group Chief Financial Officer
  • Peter Howard, General Counsel, Corporate Executive
  • Charlie Harrison, Company Secretary
  • Brian Jamieson, Independent Non-Executive Chairman of the Board
  • Donal Paul O'Dwyer, Non-Executive Independent Director
  • Eric A. Rose M.D., Non-Executive Independent Director
  • Michael R. Spooner, Non-Executive Independent Director
  • Ben-Zion Weiner Ph.D., Non-Executive Independent Director


MarketBeat Community Rating for Mesoblast limited (ASX MSB)
Community Ranking:  0.9 out of 5 ()
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  28
MarketBeat's community ratings are surveys of what our community members think about Mesoblast limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mesoblast limited (ASX:MSB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Mesoblast limited (ASX:MSB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Mesoblast limited (ASX:MSB)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Mesoblast limited (ASX:MSB)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Mesoblast limited (ASX:MSB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast limited (ASX:MSB)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Mesoblast limited (ASX:MSB)
Latest Headlines for Mesoblast limited (ASX:MSB)
Source:
DateHeadline
finance.yahoo.com logoMesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumatology
finance.yahoo.com - June 22 at 8:28 AM
finance.yahoo.com logoMesoblast Ltd. :MSB-AU: Earnings Analysis: Q3, 2017 By the Numbers : May 26, 2017
finance.yahoo.com - May 26 at 7:30 PM
nasdaq.com logoAustralia's Mesoblast posts narrower quarterly loss, rise in R&D costs
www.nasdaq.com - May 26 at 4:21 AM
finance.yahoo.com logoEdited Transcript of MSB.AX earnings conference call or presentation 24-May-17 10:00pm GMT
finance.yahoo.com - May 26 at 4:21 AM
nasdaq.com logoMesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017 - Nasdaq
www.nasdaq.com - May 24 at 6:46 PM
fool.com logoUp 100% in 2017, is the Bitcoin price an investment opportunity ... - Motley Fool Australia
www.fool.com.au - May 23 at 10:25 AM
finance.yahoo.com logoMesoblast Ltd. breached its 50 day moving average in a Bearish Manner : MSB-AU : May 16, 2017
finance.yahoo.com - May 16 at 10:24 AM
fool.com logoIs the Mesoblast limited share price about to blast off?
www.fool.com.au - April 10 at 10:21 AM
finance.yahoo.com logoSuccessful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Failure
finance.yahoo.com - April 10 at 10:21 AM
finance.yahoo.com logoFDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease
finance.yahoo.com - April 3 at 5:56 PM
finance.yahoo.com logoIndependent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Phase 3 Chronic Heart Failure Trial
finance.yahoo.com - March 31 at 9:32 AM
finance.yahoo.com logoMesoblast Raises US$40 Million
finance.yahoo.com - March 27 at 10:17 AM
fool.com logoWhy these 4 ASX shares surged higher today - Motley Fool Australia
www.fool.com.au - March 8 at 9:52 AM
fool.com logoWhy these 4 ASX shares have bolted higher today
www.fool.com.au - March 7 at 10:17 AM
finance.yahoo.com logoFDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Versus Host Disease
finance.yahoo.com - March 7 at 10:17 AM
benzinga.com logoMesoblast Presents Corporate Update and Financial...
www.benzinga.com - February 27 at 6:00 PM
biz.yahoo.com logoHalf Year 2017 Mesoblast Ltd Earnings Release - Time Not Supplied
biz.yahoo.com - February 27 at 6:00 PM
finance.yahoo.com logoPublished Study Results Show That Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease in Model of Early Rheumatoid Arthritis
finance.yahoo.com - February 13 at 10:10 AM
reuters.com logoProfile: Mesoblast Ltd (MSB.AX)
www.reuters.com - February 4 at 6:41 PM
finance.yahoo.com logoMesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 11 at 6:04 AM
globenewswire.com logoMesoblast Receives A$29.6 Million Following Share Issue to Mallinckrodt - GlobeNewswire (press release)
globenewswire.com - January 10 at 8:53 AM
barrons.com logo[$$] Mesoblast May Have an Edge on Pluristem
www.barrons.com - December 29 at 6:39 PM
fool.com logoSanta Rally fades: 11 shares you should have been watching
www.fool.com.au - December 23 at 12:01 AM
fool.com logoASX 200 closing early: 8 shares you need to watch today
www.fool.com.au - December 22 at 6:59 PM
reuters.com logoBRIEF-Mesoblast Ltd says Co and Mallinckrodt enter into agreement
www.reuters.com - December 22 at 6:59 PM
finance.yahoo.com logoMesoblast and Mallinckrodt Enter Into Equity Purchase Agreement to Exclusively Negotiate Development and Commercialization of Mesoblast's Cell Therapy Products for Chronic Low Back Pain and Acute Graft Versus Host Disease
finance.yahoo.com - December 22 at 6:59 PM
finance.yahoo.com logoMD Anderson Cancer Center and National Institutes of Health to Fund Clinical Trial Combining Two Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients
finance.yahoo.com - December 6 at 9:53 AM
fool.com logoMesoblast limited posts Q1 results: Is it a buy?
www.fool.com.au - November 15 at 9:56 AM
biz.yahoo.com logoQ1 2017 Mesoblast Ltd Earnings Release - Time Not Supplied
biz.yahoo.com - November 15 at 9:56 AM
fool.com logoMesoblast limited shares are going NUTS on trial success
www.fool.com.au - November 14 at 10:23 AM
finance.yahoo.com logoMesoblast Announces Successful Interim Futility Analysis In Phase 3 Trial For Acute Graft Versus Host Disease
finance.yahoo.com - November 14 at 10:23 AM
finance.yahoo.com logoPhase 2 Trial Results of Mesoblast’s Cell Therapy in Diabetic Kidney Disease Published
finance.yahoo.com - October 6 at 11:45 AM
fool.com logoASX 200 falls sharply: 10 shares you should have been watching
www.fool.com.au - August 29 at 10:48 AM
biz.yahoo.com logoPreliminary 2016 Mesoblast Ltd Earnings Release - Time Not Supplied
biz.yahoo.com - August 25 at 11:23 AM

Social

Social activity is not available for this stock.
This page was last updated on 7/25/2017 by MarketBeat.com Staff